[HTML][HTML] Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan
S Sathornsumetee, Y Cao, JE Marcello… - Journal of clinical …, 2008 - ncbi.nlm.nih.gov
S Sathornsumetee, Y Cao, JE Marcello, JE Herndon, RE McLendon, A Desjardins…
Journal of clinical oncology: official journal of the American Society …, 2008•ncbi.nlm.nih.govPurpose The combination of a vascular endothelial growth factor (VEGF)-neutralizing
antibody, bevaci-zumab, and irinotecan is associated with high radiographic response rates
and improved survival outcomes in patients with recurrent malignant gliomas. The aim of
these retrospective studies was to evaluate tumor vascularity and expression of components
of the VEGF pathway and hypoxic responses as predictive markers for radiographic
response and survival benefit from the bevacizumab and irinotecan therapy.
antibody, bevaci-zumab, and irinotecan is associated with high radiographic response rates
and improved survival outcomes in patients with recurrent malignant gliomas. The aim of
these retrospective studies was to evaluate tumor vascularity and expression of components
of the VEGF pathway and hypoxic responses as predictive markers for radiographic
response and survival benefit from the bevacizumab and irinotecan therapy.
Abstract
Purpose
The combination of a vascular endothelial growth factor (VEGF)-neutralizing antibody, bevaci-zumab, and irinotecan is associated with high radiographic response rates and improved survival outcomes in patients with recurrent malignant gliomas. The aim of these retrospective studies was to evaluate tumor vascularity and expression of components of the VEGF pathway and hypoxic responses as predictive markers for radiographic response and survival benefit from the bevacizumab and irinotecan therapy.
ncbi.nlm.nih.gov